Your session is about to expire
← Back to Search
RelayPro Stent-Graft for Thoracic Aortic Aneurysm (RelayPro-A Trial)
RelayPro-A Trial Summary
This trial will study the safety and effectiveness of the RelayPro Thoracic stent-graft in people with thoracic aortic aneurysms or ulcers.
RelayPro-A Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowRelayPro-A Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.RelayPro-A Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I have a disease in the lower part of the artery in my chest.I do not have conditions like aortic dissection or ruptured aneurysm.I have poor blood flow in certain areas.You are allergic to the dye used for imaging tests or any parts of the medical devices.I have undergone specific medical procedures.My blood vessels are narrowed, hardened, or twisted.I have a specific health condition like heart failure, stroke, or kidney failure.You need to have the right body shape and size for the medical device to work properly in the correct areas of your body.I am 18 years old or older.
- Group 1: RelayPro
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Is enrollment still open for this clinical experiment?
"Discerning the information available on clinicaltrials.gov, it is apparent that participant recruitment for this trial has ceased. Initially posted in May of 2017 and last updated in 2022, no new patients are being considered at this time; however there are 487 other studies still considering participants."
What primary objectives is this experiment attempting to attain?
"As described by the clinical trial sponsor, Bolton Medical, the primary outcome measured over a year-long period is stent graft patency. Furthermore, secondary outcomes including vascular access complications during treatment visits and endoleaks of all types will be observed along with rate of stent-graft migration (> 10 mm)."
How many medical centers are running this testing protocol?
"This trial is currently hosted by 15 locations, including Cleveland, Philadelphia and Hartford. To minimize the amount of travelling required for patients enrolled in this study, it is recommended to choose a site nearest you."
Share this study with friends
Copy Link
Messenger